Subtype-specific conservation of isoleucine 309 in the envelope V3 domain is linked to immune evasion in subtype C HIV-1 infection  by Lynch, Rebecca M. et al.
Virology 404 (2010) 59–70
Contents lists available at ScienceDirect
Virology
j ourna l homepage: www.e lsev ie r.com/ locate /yv i roSubtype-speciﬁc conservation of isoleucine 309 in the envelope V3 domain is linked
to immune evasion in subtype C HIV-1 infection
Rebecca M. Lynch a, Rong Rong b,e, Bing Li e, Tongye Shen i, William Honnen g, Joseph Mulenga h,
Susan Allen c,d, Abraham Pinter g, S. Gnanakaran j, Cynthia A. Derdeyn b,e,f,⁎
a Immunology and Molecular Pathogenesis Program, Emory University, Atlanta, GA 30329, USA
b Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA 30329, USA
c Department of Global Health, Emory University, Atlanta, GA 30329, USA
d Rollins School of Public Health, Emory University, Atlanta, GA 30329, USA
e Yerkes National Primate Research Center, Emory University, Atlanta, GA 30329, USA
f Emory Vaccine Center, Emory University, Atlanta, GA 30329, USA
g Public Health Research Institute, UMDNJ-New Jersey Medical School, Newark, NJ 07103, USA
h Zambia Blood Transfusion Service, Lusaka, Zambia
i Department of Biochemistry, Cellular & Molecular Biology, University of Tennessee, Knoxville, TN 37996, USA
j Theoretical Division, Los Alamos National Laboratory, Los Alamos, NM 87545, USA⁎ Corresponding author. Emory Vaccine Center, Emory
Suite 1024, Atlanta, GA 30329, USA. Fax: +1 404 727 9
E-mail address: cynthia.derdeyn@emory.edu (C.A. D
0042-6822/$ – see front matter © 2010 Elsevier Inc. A
doi:10.1016/j.virol.2010.04.010a b s t r a c ta r t i c l e i n f oArticle history:
Received 25 February 2010
Returned to author for revision 17 March 2010
Accepted 10 April 2010





EnvelopeThe V3 region of the HIV-1 envelope (Env) glycoprotein gp120 is a key functional domain yet it exhibits distinct
mutational patterns across subtypes. Here an invariant residue (Ile 309) was replaced with Leu in 7 subtype C
patient-derived Envs from recent infection and 4 related neutralizing antibody escape variants that emerged
later. For these 11 Envs, I309L did not alter replication in primary CD4 T cells; however, replication inmonocyte-
derived macrophages was enhanced. Infection of cell lines with low CD4 or CCR5 revealed that I309L enhanced
utilization of CD4but didnot affect the ability touseCCR5. ThisCD4-enhancedphenotype trackedwith sensitivity
to sCD4, indicating increased exposure of the CD4 binding site. The results suggest that Ile 309 preserves a V3-
mediatedmasking function that occludes the CD4 binding site. The ﬁndings point to an immune evasion strategy
in subtype C Env to protect this vulnerable immune target.University, 954 Gatewood Rd.,
316.
erdeyn).
ll rights reserved.© 2010 Elsevier Inc. All rights reserved.Introduction
HIV-1 groupM is a collection of genetically diverse viruses that have
been classiﬁed into 9major subtypes as well asmultiple circulating and
unique recombinant forms (for a complete listing see http://www.hiv.
lanl.gov). The envelope (env) gene is a major source of this genetic
diversity, varying by approximately 10% within an individual, 20%
within a subtype, and 35% between subtypes (Korber et al., 2001). The
product of the env gene is a 160 kDa polyprotein precursor that is
proteolytically processed into individual subunits, gp41 and gp120,
which associate non-covalently to form trimeric ‘spikes’ on the surface
of the virion. The gp120 subunit protrudes from the virion surface, and
contains thebinding sites for theCD4 receptor and the coreceptors CCR5
or CXCR4. The gp120 is also themajor target for neutralizing antibodies
(Nab), but its genetic variability poses a signiﬁcant obstacle for vaccine-
induced protection (Binley et al., 2008; Gorny, 2004; Gray et al., 2009;
Scheid et al., 2009). Much of what is currently known about the
organization of gp120 is based on crystal structures of a truncated, de-glycosylated, CD4-bound subtype B core or a truncated, glycosylated,
unliganded SIV core (Chen et al., 2005; Kwong et al., 2000, 1998). The
structure and position of the ﬁve ‘hyper-variable’ domains (V1–V5) on
gp120 have been difﬁcult to determine because of their conformational
ﬂexibility; it is, therefore, not fully understoodhow these domains could
inﬂuence the overall conformation and immunogenicity of the native
protein. Consequently, the positions, inter-molecular interactions, and
genetic diversity of the hyper-variable domains could lead to subtle but
important structural differences, particularly between viral subtypes
(Gnanakaran et al., 2007; Gray et al., 2007; Lynch et al., 2009; Patel et al.,
2008; Rong et al., 2007b).
Of theﬁvehyper-variabledomains, V3 is relatively conserved (Huang
et al., 2005) and does not exhibit the dramatic insertions, deletions, and
shifts in potential N-linked glycosylation sites that are characteristic of
the V1V2 and V4 domains. Perhaps this reﬂects that the V3 domain
participates directly in coreceptor binding,which is a critical step in viral
entry (Cardozo et al., 2007; Cormier and Dragic, 2002; Trkola et al.,
1996). Nevertheless, the amino acid sequence of V3 and its mutational
pattern exhibit differences across subtypes (Felsovalyi et al., 2006;
Gaschen et al., 2002; Korber et al., 1994; Patel et al., 2008). One striking
example is that subtype A and C V3 domains contain a highly conserved
GPGQ amino acid motif at the crown, while GPGR is predominant in
Table 1
Subject information.






106F 8-Jun-98 No 129 ND NT
55F 13-Aug-98 No 90 ND NT
109F 16-Mar-00 No 96 ND NT
153M 13-Mar-02 Yes 88 ND 24-months
185F 17-Aug-02 Yes 11 33 23-months
221M 7-Mar-03 Yes 100 31 23-months




60 R.M. Lynch et al. / Virology 404 (2010) 59–70subtype B Envs (Korber et al., 1994; Stanﬁeld et al., 2006). Subtype D
Envs, on the other hand, carry a mixture of residues at the R/Q position
(www.hiv.lanl.gov). The subtype B V3 domain facilitates a switch in
tropism, from CCR5 to CXCR4 usage in about 50% of patients (Connor
et al., 1997; Richman and Bozzette, 1994; Schuitemaker et al., 1992;
Tersmette et al., 1989),whereasCXCR4usage among subtypeCviruses is
infrequent, even in advanced stage patients (Choge et al., 2006; Cilliers
et al., 2003; Coetzer et al., 2006; Isaacman-Beck et al., 2009;Morris et al.,
2001; Sullivan et al., 2008). Consistent with possible functional
constraints, the subtype C V3 domain exhibits less sequence variation
compared to subtype B (Gaschen et al., 2002; Gilbert et al., 2005; Korber
et al., 1994; Patel et al., 2008; Rong et al., 2007b; Stanﬁeld et al., 2006).
Even during escape from autologous Nab in subtype C HIV-1 infection,
the V3 domain remains remarkably conserved amid ongoing sequence
evolution in other Env regions (Moore et al., 2009; Rong et al., 2009). It
has recently been shown that distinct mutational patterns in subtype B
and C lead to conformational differences as well (Patel et al., 2008).
Interestingly, position 309 in V3 exhibits extreme conservation as Ile in
subtype C but in subtype B, Leu, Met, and Val also occur with relative
frequency (Patel et al., 2008). Thus, while lineage-speciﬁc genetic
differences in the V3 domain have been ﬁrmly established, their
underlying biology is not clearly understood.
Here we have begun to explore the biological basis for conserva-
tion of V3 sequence by creating an I309L substitution in a panel of
eleven diverse, patient-derived subtype C Envs that includes recently
transmitted viruses and deﬁned autologous Nab escape variants. We
evaluated changes in both function and antigenicity of the wildtype
andmutated Envs and uncovered evidence suggesting that in subtype
C, I309 participates in immune evasion by masking the CD4bs and
possibly other vulnerable sites, even though this residue is not critical
for interactions with CCR5.Fig. 1. Alignment of V3 sequences from subject Envs. Amino acid sequences of the V3 doma
using SeqPublish (Los Alamos Database) and are shown in comparison to the consensus sequ
red and the four Nab escape variants from a longitudinal time point two years post-infection
residues that are the same as the subtype C consensus sequence. A green box designates theResults
I309L was created in a representative panel of diverse subtype C Envs
The major goal of this study was to investigate the biological effects
of mutating Ile 309 in Envs of HIV-1 subtype C, in which this residue is
99% conserved. We chose Leu because this amino acid occurs naturally,
albeit in less than 1% of subtype C Envs, and has been associated with
structural changes in V3 (Stanﬁeld et al., 2006).We therefore selected a
panel of seven Envs that were each cloned during acute/early infection
from a different subject enrolled in the Zambia–Emory HIV Research
Project (Table 1). The newly transmitted Envs were cloned within
129 days of the last seronegative test, with Envs from 185F, 221M, and
205F being within an estimated 48 days of infection. To broaden the
relevance of this study,we also included four Envs cloned at a timepoint
between23and25 monthsafter infection thathaddeveloped resistance
against the contemporaneous autologous neutralizing antibody (Nab)
pool ((Rong et al., 2009) anddata not shown) (Table 1). These later Envs
allowed us to evaluate the effects of the I309L mutation speciﬁcally
within Envs known to have adapted to Nab immune pressure during
natural infection. Supplemental Fig. 1 demonstrates that all of the Envs
cluster phylogenetically as subtype C, and that their genetic diversity is
representative of subtype C variants circulating across multiple
geographic regions. This ﬁgure also shows that the newly transmitted
Envs from subjects 205F, 153M, 185F, and 221M each cluster with the
Nab escape variant from the same patient. The I309L mutation was
created in the V3 domain of each of the 11 Envs (Fig. 1) and used in the
biological studies described in the following sections.
The I309L mutation does not decrease replication in primary CD4 T cells
Purifying selection imposedupon I309 could indicate that changes at
this position are not tolerated because they decrease replication
capacity. We therefore evaluated whether the I309L change would be
detrimental to replication in activated CD4 T cells. Ten of the eleven
Envs, with and without I309L, were transferred into a replication
competent NL4.3 proviral backbone and used to infect PBMC enriched
for CD4 T cells by CD8 depletion. A replication competent virus
containing185F 23-month EnvPL1.1 could not be generated using this
systemdue to internal restriction sites. Supernatantwas collected every
two days and viral p24 was quantiﬁed for a measure of viral replication
(Fig. 2A and Suppl. Fig. 2). The subtype C provirus MJ4 was used as a
positive control for replication in CD4 T cells (Ndung'u et al., 2001).
The acute/early subtype C Envs mediated replication with variable
magnitude and kinetics, but day 10 represented the peak p24 level for
themajority of the subtype C Envs (Fig. 2A and Suppl. Fig. 2). Therefore,in from the 11 patient-derived Envs used in the mutagenesis experiments were aligned
ence for subtype C. The 7 Envs from an acute/early time point of infection are shown in
are shown in blue. The consensus subtype C sequence is shown in black. Dashes indicate
I309 residue that was mutated to an L309 in each Env using site-directed mutagenesis.
Fig. 2. Replication of virus containing a wildtype and I309L mutated Envs in PBMC. 10
wildtype and 10 I309L mutated Envs were placed into a replication competent NL4.3
backbone and used to infect CD8-depleted human PBMC; representative graphs of 3 of
these pairs are shown in panel (A). Viral p24 antigen production in the supernatant was
measured by ELISA and is plotted (pg/ml) on the vertical axis on a log10 scale while
days post-infection are on the horizontal axis. Mock-infected (squares) and positive
control virus NL4.3 (triangles) are shown in black. Wildtype Envs are blue and I309L
mutant Envs are green. The error bars represent two independent experiments using
two different donors. Total p24 at day 10 of infection is shown as a dot plot (B). The
residue at position 309 is indicated on the horizontal axis, and a comparison of p24
antigen levels between I309 Envs (blue) and L309 (green) Envs was performed using
Graphpad Prism. Each dot represents the mean p24 for one Env. The p-value was
determined using a paired Wilcoxon test. The p24 level for the positive control virus
NL4.3 is represented by a black arrow.
Fig. 3. Replication of I309 and I309L Env viruses in MDM. 10 wildtype and 10 I309L
mutated Envs were placed into a replication competent NL4.3 backbone and used to
infect CD8-depleted human PBMC; representative graphs of 3 of these pairs are shown
in panel (A). Viral p24 antigen production in the supernatant was measured by ELISA
and is plotted (pg/ml) on the vertical axis on a log10 scale while days post-infection are
on the horizontal axis. Mock-infected is shown in black squares, negative control virus
NL4.3 (triangles) and positive control virus YU-2 (diamonds) are shown in red,
wildtype I309 Envs are blue and I309L mutant Envs are green. The error bars represent
two independent experiments from two different donors. Total p24 at day 13 of
infection is shown as a dot plot (B). The residue at position 309 is indicated on the
horizontal axis, and a comparison of p24 antigen levels between I309 Envs (blue) and
L309 (green) Envs was performed using Graphpad Prism. Each dot represents the mean
p24 for one Env. The p-value was determined using a paired Wilcoxon test. The p24
level for the positive control viruses YU-2 (shown as a red dot) and the negative control
virus NL4.3 are represented by black arrows.
61R.M. Lynch et al. / Virology 404 (2010) 59–70this time point was used to compare the overall replication between
paired sets of wildtype and I309L mutant Envs. Each wildtype Env and
its I309L mutant displayed comparable replication kinetics and p24
levels (Fig. 2A andSuppl. Fig. 2), and therewasno statistical difference in
day10p24 levels betweenof the twogroups (Fig. 2B). Toensure that theI309L mutation had not reverted, the V3 domain of each mutant virus
was sequenced using virion-associated RNA in supernatant collected at
day 10 during one experiment (data not shown). This result
demonstrates that I309L-containing Envs are replication competent in
activatedCD4T cells, and suggests that the strongconservationof I309 is
62 R.M. Lynch et al. / Virology 404 (2010) 59–70not due to a detrimental effect on viral replication, at least as measured
by this in vitro assay.
The I309L mutation leads to a moderate enhancement of replication in
monocyte-derived macrophages
In addition to CD4 T cells, human monocyte-derived macrophages
(MDM) can also serve as a target cell for HIV-1 in vivo. We therefore
evaluated whether I309L altered in vitro replication in MDM cultures.
For these experiments, the subtype B Env YU-2 was used as a positive
control for replication inMDM, andNL4.3wasused as a negative control
(Fig. 3A and Suppl. Fig. 3) (Li et al., 1992). None of the subtype C Envs
replicated as efﬁciently as the ‘control’ strain YU-2, which is consistent
with our previousﬁnding that subtypeCEnvs,while CCR5-tropic, donot
infect MDM with high efﬁciency (Isaacman-Beck et al., 2009).
Nevertheless, using p24 level at day 13 post-infection for comparison,
the I309L Envs overall replicated to moderately higher levels than their
wildtype counterparts (Fig. 3B; p=0.02). This enhanced ability to
replicate in MDM cultures could be linked to augmented usage of low
amounts of CD4 found on these cells, as compared to levels found on
T cells (Bannert et al., 2000; Collman et al., 1990; Duenas-Decamp et al.,
2009; Thomas et al., 2007).
The I309L mutation confers increased entry into a cell line expressing
low CD4
We next investigated whether differences in infection efﬁciency
would be observed in HeLa-based cell lines that express known
quantities of CD4 and CCR5. JC.53 cells, which express high levels of
CCR5 and CD4, were used to determine relative infectivity in two
different cell lines: JC.10, which express low CCR5/high CD4, andFig. 4. Lower dependence on CD4 but not CCR5 levels for entry by I309L Envs. The
infectivity of the 11 wildtype and 11 I309Lmutated pseudotyped Envs was measured in
HeLa cell lines JC.10 with high CD4 and low CCR5 (A) and RC.49 expressing low CD4 and
high CCR5 (B). The relative infectivity compared to JC.53 cells, which express high CD4
and high CCR5, was determined by provirally-encoded luciferase and is shown on the
vertical axis. The I309 wildtype Envs are blue while the I309L mutated Envs are green.
Each point represents the mean relative infectivity of an individual Env pseudovirus
from 2 independent experiments. A paired Wilcoxon test was used to determine the p-
value.RC.49, which express high CCR5/low CD4 (see Materials and
methods) (Platt et al., 1998). These cell lines were infected with
pseudoviruses created by expressing the wildtype or I309L mutant
Envs with an HIV-1 env-deﬁcient backbone that encodes luciferase.
Under the condition of high CD4 and limited CCR5, there was no
statistically signiﬁcant difference between the wildtype and I309L
Envs in ability to enter the JC.10 cells (Fig. 4A). There was one pair of
Envs from subject 221 for which the I309L did appear to decrease
infectivity, although this effect may be due to an inherent property of
the V3 loop (perhaps the D321, see Fig. 1) in these two Envs. Overall,
however, infectivity of JC.10 cells was decreased by approximately 10-
fold for all Envs, compared to the JC.53 cells (high CCR5, high CD4),
suggesting that the wildtype and I309L Envs were equally dependent
on CCR5 for entry into JC.10 cells. Dependence on CCR5was conﬁrmed
using the HI-J cell line, which expresses CD4 and endogenous CXCR4
but no CCR5 (data not shown). When CD4 levels were reduced,
however, the I309L containing Envs consistently had higher relative
infectivity in the RC.49 cells, ranging from a 1.1- to an 18.6-fold
increase over the matched wildtype Env (Fig. 4B; p=0.003). It should
be noted that the infectivity of all Envs for RC.49 cells was generally
about 1% of that achieved on the JC.53 cells. Thus, all of the Envs were
highly dependent on CD4 levels, consistent with other studies by our
group using patient-derived subtype C Envs from acute/early and
chronic infection (Alexander et al., 2010). The I309L mutation did not,
therefore, “pre-trigger” the coreceptor binding domain, leading to
CD4 independence, as has been described for subtype B Envs carrying
non-consensus residues at position 309 (Decker et al., 2005; Zhang
et al., 2002). Thus, although both I309L and wildtype Envs were
inefﬁcient at infecting cells with limiting levels of CD4, the I309L Envs
consistently had higher relative infectivity, suggesting more efﬁcient
binding to CD4 and/or increased exposure of the CD4bs.
The I309L mutation confers increased sensitivity to sCD4
Patient-derived virus Envs are typically resistant to inhibition by the
soluble form of the CD4 receptor, sCD4, reﬂecting the cryptic nature of
the CD4 binding site (CD4bs) (Ashkenazi et al., 1991; Bures et al., 2002;
Daar et al., 1990; Moore et al., 1993, 1992; Pugach et al., 2004; Willey
et al., 1994; Wu et al., 2009). However, the ability to infect MDM and
RC.49 cells has been associated with increased sensitivity to sCD4
inhibition (Duenas-Decamp et al., 2009; Peters et al., 2008, 2006). Fig. 5
demonstrates that all of the wildtype Envs were relatively resistant to
sCD4 out to 100 nM in a single round pseudovirus assay. The I309L
substitution, however, led to an almost universal increase in sCD4
sensitivity, although themagnitude varied between Envs (Fig. 5A). For 9
of the 11 Envs, I309L resulted in an increase in sensitivity compared
againstwildtypeat thehighest concentration of sCD4(100 nM).Overall,
viral infectivity was signiﬁcantly lower with the I309Lmutation at both
100 nM and 20 nM concentrations of sCD4 (Fig. 5B; p=0.001 and
p=0.005, respectively), suggesting a consistent increase in exposure of
theCD4bs in themutantEnvs as compared to thewildtypeEnvs. Binding
to CD4 was further assessed by incubating the pseudotyped Envs with
an anti-CD4monoclonal antibody B13.8.2, and subsequently calculating
the concentration of antibody necessary to reduce viral infectivity by
50% (IC50). The I309L Envs required higher concentrations of anti-CD4
to inhibit infection (with a higher IC50) than wildtype, conﬁrming their
more efﬁcient utilization of the CD4 receptor (Fig. 5C; p=0.01).
The I309L mutation moderately increased sensitivity to monoclonal
antibodies directed against V3 and a CD4-induced epitope
If I309L induces conformationally based changes in gp120 that
increase exposure of the CD4bs, we hypothesized that other Env
domains could also be affected. Patient-derived Envs, and in particular
those of subtype C, are typically refractory to neutralization by anti-V3
antibodies (Binley et al., 2004; Davis et al., 2009; Keele et al., 2008;
Fig. 5. I309L mutation increases sCD4 sensitivity in multiple subtype C Envs. The parent and wildtype Envs were assessed for sensitivity to sCD4 using pseudoviruses (A). Mutant
I309L Envs are shown by green lines and wildtype Envs are shown by blue lines. Each line on the graph represents an individual Env pseudovirus. Percent viral infectivity compared
to no sCD4 is shown on the vertical axis and was calculated from luciferase units by dividing virus-infected wells in the presence of inhibitor by the virus-infected well in the absence
of inhibitor. The concentration of sCD4 (in nanomolar) is plotted on the horizontal axis on a log10 scale. Error bars represent the standard error of the mean of at least 2 independent
experiments. Vertical point plots of the mean percent viral infectivity for each Env pseudovirus at 100 nM and 20 nM sCD4 respectively were generated using Graphpad Prism (B)
while the IC50 (μg/ml) of pseudovirus in the presence of anti-CD4 binding antibody B13.8.2 is shown in (C). I309 Envs in blue were compared to L309 Envs in green. A paired
Wilcoxon test was performed to determine the p-value.
63R.M. Lynch et al. / Virology 404 (2010) 59–70Moore et al., 2008; Salazar-Gonzalez et al., 2009; Wu et al., 2008).
Therefore, a pool of three anti-V3directedmonoclonal antibodies from
Indian patients infected with subtype C viruses were used to assess
changes in susceptibility to V3-targeted neutralization. In 6 of the 11
Envs, there was an increase in sensitivity to anti-V3 mediated
neutralization with the I309L mutation (Fig. 6A), suggesting a localunmasking of the V3 domain. Taken as awhole, when infectivity at the
highest concentration of antibody (10 μg/ml) was compared in a
pairwise manner, there was a statistically signiﬁcant difference
between wildtype and mutant Envs (Fig. 6B; p=0.04).
We next investigated whether the I309L Envs were also more
susceptible to sCD4-triggering of the coreceptor binding site, which
Fig. 6. I309L increases neutralization by anti-V3 antibodies. Neutralization sensitivity to a pool of three monoclonal antibodies against V3 derived from subtype C infected subjects in
India was assessed for each mutant I309L and wildtype Env (A). The data is shown as the percent viral infectivity (luciferase units in the presence of antibody divided by in the
presence of control anti-parvovirus antibody) on the y-axis. The concentration of themonoclonal antibodies is shown on the x-axis on a log-10 scale. Mutant I309L Envs are shown by
green lines andwildtype Envs are shown by blue lines. Each line on the graph represents an individual Env pseudovirus. Error bars represent the standard error of themean of at least
2 independent experiments. A vertical point plot of the mean percent viral infectivity at 10 μg/ml of the monoclonal pool was generated using Graphpad Prism (B). I309 Envs in blue
were compared to L309 Envs in green. A paired Wilcoxon test was performed to generate the p-value shown.
64 R.M. Lynch et al. / Virology 404 (2010) 59–70contains an epitope recognized by themonoclonal antibody 17b (Thali
et al., 1993). The Envs were pre-incubated with their IC50 of sCD4, or
100 nM if an IC50 was not determined, and then neutralization by 17bwas evaluated. Four of the 11 Envs showed a moderate increase in
neutralization sensitivity to 17b after incubation with sCD4 (Fig. 7A).
Overall the difference between the wildtype and I309L Envs reached
Fig. 7. I309L slightly increases neutralization of pre-triggered Envs by an anti-coreceptor binding site antibody 17b. Mutant I309L and wildtype Envs pseudoviruses were incubated
with their cognate IC50 nM of sCD4 (100 nM of sCD4 if 50% inhibition was never reached), and then neutralization sensitivity was assessed bymonoclonal antibody 17b (A). The data
is shown as the percent viral infectivity (luciferase units in the presence of antibody divided by in the presence of control anti-parvovirus antibody) on the y-axis. The concentration
of 17b is shown on the x-axis on a log-10 scale. Mutant I309L Envs are shown by green lines and wildtype Envs are shown by blue lines. Each line on the graph represents an
individual Env pseudovirus. Error bars represent the standard error of the mean of at least 2 independent experiments. A vertical point plot of the mean percent viral infectivity at
2 μg/ml of 17b was generated using Graphpad Prism (B).Wildtype Envs in bluewere compared to I309L Envs in greenwhile themean infectivity for each group is represented by the
black horizontal line. A paired Wilcoxon test was performed to generate the p-value shown.
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66 R.M. Lynch et al. / Virology 404 (2010) 59–70the borderline of statistical signiﬁcance in a paired analysis (Fig. 7B;
p=0.05), suggesting that this mutation did also affect efﬁciency with
which the coreceptor binding site was formed, albeit in a context
dependent manner.
Discussion
In sequences representative of established infection, the subtype C
V3 domain is more conserved than other subtypes. Consistent with
this observation, we recently demonstrated that V3 remained
remarkably conserved during the ﬁrst two years of infection despite
increasing sequence variation in V1V2, the gp120 outer domain, and
gp41 (Rong et al., 2009). In the present study, we investigated the
underlying biological basis for the conservation of V3 by focusing
speciﬁcally on a residue that can exhibit high entropy in subtypes
other than C. While this and other subtype-speciﬁc mutational
patterns in V3 have been well established (Gaschen et al., 2002;
Gilbert et al., 2005; Korber et al., 1994; Patel et al., 2008; Rong et al.,
2007b; Stanﬁeld et al., 2006), this study is among the ﬁrst to delve into
the biology that drives these observations.
Replication is not dependent on conservation of I309
As Ile is the highly conserved consensus residue for position 309 in
subtype C, we evaluated whether a conservative substitution of Leu
would lead to any defect reﬂected in the capacity for in vitro
replication. Replication and spread in two primary target cells, CD4
T cells and MDM, was not overtly reduced by the I309L substitution.
Although, it should be noted that we could not rule out subtle
differences in replication kinetics between the wildtype and I309L
mutants that might have been evident in a more sensitive growth
competition assay. Overall, the subtype C Envs replicated to higher
levels in CD4 T cells compared to MDM, suggesting that none of the
wildtype Envs were inherently macrophage-tropic. This ﬁnding is
consistent with our previous results in which subtype C Envs from
recently and chronically infected subjects mediated single round
infection of MDM much less efﬁciently than CD4 T cells (Isaacman-
Beck et al., 2009). Low efﬁciency replication inMDM compared to CD4
T cells has been attributed to an inability of patient-derived Envs to
utilize the low CD4 levels expressed by MDM (Bannert et al., 2000;
Collman et al., 1990; Duenas-Decamp et al., 2009; Thomas et al.,
2007). Themoderate enhancement of replication inMDMwhen I309L
was present suggests that this mutation could have altered the viral
interaction with CD4. Indeed, a majority of the I309L mutant Envs
more efﬁciently infected a cell line expressing a low level of CD4,
focusing the effects of the mutation on utilization of CD4. Taken
together, these results suggest that subtype-speciﬁc conservation of
I309 is not driven by a detrimental effect on replication in CD4 T cells
or MDM. Rather, this ﬁnding is consistent with the idea that Env
residues that are critical for viral entry, like the GPG motif in V3, are
conserved across all subtypes (Freed et al., 1991). Thus, subtype-
speciﬁc conservation of I309 is more likely driven by properties that
differ between subtypes, such as the antigenic nature of V3 and other
Env regions.
Conservation of I309 prevents exposure of neutralization targets
sCD4 sensitivity was used in this study as a surrogate for exposure
of the CD4bs, and all but two Envs (both from subject 185F) became
more sensitive to sCD4 when I309L was introduced. This ﬁnding
supports the idea that V3, speciﬁcally I309, modulates exposure of the
CD4bs, and is consistent with data from other studies (Agrawal-
Gamse et al., 2009; Hwang et al., 1992; Lynch et al., 2009; Wyatt et al.,
1992). Increased exposure of the CD4bs does not necessarily indicate
that these Envs would be more sensitive to CD4bs-directed anti-
bodies, however, a monoclonal targeting this region and capable ofneutralizing these subtype C Envs was not available to test this
hypothesis. However, increased sCD4 sensitivity was consistently
observed, and this was accompanied by increased neutralization via
V3 and CD4-induced epitopes to varying degrees. It has been shown
that HIV-1 infected patients develop high titers of anti-CD4 induced
and anti-V3 antibodies, and more variable titers of anti-CD4bs
antibodies (Binley et al., 2008; Davis et al., 2009; Decker et al.,
2005; Gray et al., 2009; Li et al., 2009; Moore et al., 2008; Scheid et al.,
2009). It is plausible that I309L Envs could be more susceptible to
these types of antibodies in vivo, and would therefore be selected
against by immune pressure. It is important to note that we were
unable to detect an increase in sensitivity to autologous patient
plasma with I309L (data not shown). However, only the dominant
circulating Nab speciﬁcities are measured in assays that utilize patient
plasma, while other lower titer speciﬁcities may also exert selective
pressure (Blish et al., 2009; Moore et al., 2009; Rong et al., 2009;
Scheid et al., 2009). Alternatively, I309 could protect immunogenic
structures so effectively that antibodies against these hidden epitopes
are never induced. Since the number and potency of monoclonal
antibodies available to probe differences between wildtype and I309L
Envs was limited, the effect of I309L on neutralization sensitivity
could be underestimated. Thus, even a subtle increase in susceptibility
to neutralization by sCD4, anti-V3, and anti-CD4i monoclonal
antibodies in vitro could reﬂect a substantial growth disadvantage in
vivo. In fact, the differences in neutralization sensitivity between
parent and mutant Envs were subtle, trending toward signiﬁcance,
but really driven by the Env from subject 55F. The impact of the L309
mutation was dramatic in this Env, a fact that may result from the
unusual M307 residue (see Fig. 1) and highlights how many changes
in Env sequence are context dependent and rarely result in a globally
reproducible phenotype. We also acknowledge, that overall neutral-
ization sensitivity and immune evasion is clearly inﬂuenced by
multiple Env domains, as shown by our group and others (Blish et al.,
2008; Moore et al., 2008, 2009; Pinter et al., 2004; Rong et al., 2007a,
2009; Wei et al., 2003).
V3-mediated masking of the CD4 binding site
We previously highlighted a cluster of hydrophobic residues
ﬂanking the V3 tip (anchored by residues I307, I309, and F317) that
are highly conserved in subtype C sequences in the database and are
largely restricted to hydrophobic amino acids across subtypes (Gilbert
et al., 2005; Lynch et al., 2009; Rong et al., 2007b; Stanﬁeld et al.,
2006). Coarse-grained calculations suggested that this hydrophobic
cluster has the potential to interact withmultiple gp120 core residues,
several of which are proximal to the CD4 binding site and may impact
CD4 binding (Lynch et al., 2009). Based on these previous observa-
tions, and our current experimental results, we propose that the I309L
substitution perturbs the hydrophobic cluster and, by altering the
position of the V3 loop, impacts the CD4bs. Thus, for subtype C viruses,
maintaining this residue could represent an intrinsic strategy of
immune evasion, particularly concerning Nab recognition of the
CD4bs. Consistent with this idea, I309 was not critical for viral
replication or usage of CCR5, but its major effect was manifested in
exposure of the CD4bs prior to receptor ligation.
Thus, V3 in subtype C Env could be placed in an optimal position to
contribute to immune evasion prior to CD4 binding and additionally aid
viral entry after CD4 binding. This theory provides a biologically
plausible explanation for the I309L CD4 enhanced phenotype described
here, aswell as a compelling reason for the unique conservation pattern
of speciﬁc residues within the subtype C V3 domain that may not be
critical for viral entry functions. The idea of conformational masking of
neutralization targets is not new; and others have demonstrated
concealment of epitopes on the native trimer (Binley et al., 2008;
Davis et al., 2009; Moore et al., 2008; Wu et al., 2008, 2009). It is
important tonote that this tactic ofV3-masking could alsooccur inother
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speciﬁc feature of subtypeCEnvsmay limit their inherentneutralization
susceptibility to certain types of antibodies and could also inﬂuence
their immunogenicity, which is of interest for vaccine design.
Materials and methods
Env clones
Details of the ZEHRP cohort, sample collection, and processing have
been described previously (Derdeyn et al., 2004; McKenna et al., 1997;
Trask et al., 2002). The Envs studied here were derived from seven newly
infected subjects from this cohort (185F, 153M, 205F, 221M, 109F, 106F,
and 55F). The Emory University Institutional Review Board, and the
University of Zambia School of Medicine Research Ethics Committee
approved informed consent and human subjects protocols. None of the
subjects received antiretroviral therapy during the evaluation period. PCR
ampliﬁcation and cloning of the Envs has been described (Derdeyn et al.,
2004; Haaland et al., 2009; Rong et al., 2009). The env genes were cloned
into one of the CMV-driven expression plasmids pCR3.1 or pcDNA 3.1/
V5-His TOPO (Invitrogen), which were then used to generate viral
pseudotypes. All Envs were derived from plasma or PBMC DNA
according to protocols previously described (Li et al., 2006) and are
subtype C. Nucleotide sequences (either V1–V4 or full-length) have been
deposited into Genbank under the following accession numbers: 55
FPB4a AY423973, 106 FPB9 AY424163, 109 FPB32 AY424141, 205FPB
12MAY05ENV5.1 GQ485442, 205FPL27MAR03ENV5.2 GQ485418,
185FPL 10JUL04ENV1.1 GQ485388, 185FPB 24AUG02 ENV3.1
GQ485314, 153MPL 13MAR02 ENV5.1 HM068596, 153MPL 13MAR04
ENV4.1 HM068597, 221MPL 7MAR03 ENV2.1 HM068598, 221MPL
26FEB05 ENV3.1 HM068599. All amino acid positions are based on
HXB2 gp160 numbering.
PCR-based site mutagenesis
To generate I309L mutations, PCR-directed site mutagenesis was
performed using two overlapping primers that contained the mutated
sequence for each Env using a strategy similar to that described in (Rong
et al., 2007a). Brieﬂy, each env gene (plus Rev and partial Nef coding
sequences) was ampliﬁed using primer sequences similar to the
following, which were used with 185F 0-Month EnvPB3.1 (substituted
nucleotide is underlined and HXB2 locations are provided): 7124–7162
(5′-CAA TAA TAC AAG GAA AAG TGT GAG ACT AGG ACC-3′) and 7134–
7167 (5′-GTC CTG GTC CTA GTC TCA CAC TTT TCC-3′). The ampliﬁcation
conditionswere: 1 cycle of 95 °C for 30 s; 18 cycles of 95 °C for 30 s; 45 °C
for 1 min (optimal annealing temperature was determined for each
primer set), and 68 °C for 9 min; storage at 4 °C. The 50 μl PCR reactions
contained 100 ng of each primer, 10 ng of the plasmid template, 0.2 mM
dNTP, and 1× reaction buffer. pfuUltra II FusionHotstart DNApolymerase
(Stratagene) was used to generate the PCR amplicons, which were
digested with DpnI to remove contaminating template DNA, and then
transformed into maximum efﬁciency XL2-Blue ultracompetent cells
(N5×109 cfu/μg DNA; Stratagene) so that the DNA volume did not
exceed 5% of the cell volume. The entire transformation was plated onto
LB-Ampicillin agar plates, generally resulting in 10 to 50 colonies.
Colonies were inoculated into LB-Ampicillin broth for overnight
cultures and the plasmid was prepared using the QIAprep Spin
Miniprep Kit. Each plasmid was screened for biological function as
previously described (Derdeyn et al., 2004; Li et al., 2006). Brieﬂy,
600 ng of Env DNA was co-transfected into 293T cells along with
1200 ng of an Env-deﬁcient subtype B proviral plasmid, pSG3ΔEnv,
using Fugene-6 according to the manufacturer's instructions (Hoff-
man-La Roche). Seventy-two hours later, the transfection supernatant
was transferred to JC53-BL (TZM-bl) indicator cells. At 48 h post-
infection, each well was scored positive or negative for blue foci using
b-gal staining. For clones that produced functional Env pseudotypes,the plasmids were re-transfected into 293T cells on a larger scale to
produce a working pseudotype virus stock. Transfection supernatants
were collected at 48 h post-transfection, clariﬁed by low speed
centrifugation for 20 min, aliquoted into 0.5 ml or less portions, and
stored at −80 °C. The titer of each pseudotyped virus stock was
determined by infecting JC53-BL cells with 5-fold serial dilutions of
virus as described previously (Derdeyn et al., 2004; Li et al., 2006). All
env sequences were conﬁrmed by nucleotide sequencing.
Virus neutralization and inhibition assays
Neutralization assays using sCD4,monoclonal 17b, and apool of anti-
V3 monoclonal antibodies derived from subtype C infected Indian
patients were performed using viral pseudotypes to infect JC53-BL
(Tzm-bl) indicator cells using a luciferase readout as described
previously (Derdeyn et al., 2004; Li et al., 2006; Rong et al., 2007a,b,
2009).Ahuman IgG isotype controlwasused in allmonoclonal antibody
experiments. Brieﬂy, 2000 IU of pseudovirus was incubated for 1 h in
DMEM+10% FBS (Hyclone)+40 μg/ml DEAE-Dextran with serial
dilutions of sCD4 or monoclonal antibody and 100 μl was then added
to the indicator cells for a 48 h infection before being lysed and
evaluated for luciferase activity. To pre-trigger Envs, the pseudovirus
was incubated for 1 hwith either its IC50 of sCD4 or 100 nMsCD4 if 50%
inhibition was not achieved. After incubation for another hour with
serial dilutions of 17b, 100 μl of sCD4-17b-virus was added to JC-53BL
cells for a 48 h infection. The 17bmonoclonal antibody (contributed by
Dr. James Robinson) (Thali et al., 1993) and sCD4-183 (2-domain)
(contributed by Progenics Pharmaceuticals) (Garlick et al., 1990) were
obtained from the NIH AIDS Research and Reference and Reagent
Program, Division of AIDS, NIAID, NIH. The anti-CD4 antibody B13.8.2
was kindly provided by Dr. Quentin Sattentau (University of Oxford)
(Sattentau and Moore, 1995). A pool of three monoclonal antibodies
against the V3 domain isolated from Indian patients infected with
subtype C viruses was contributed by Dr. Susan Zolla-Pazner.
Replication in CD4 and monocyte-derived macrophages (MDM) using
an NL4.3 proviral cassette
A panel of Envs was subcloned into a replication competent NL4.3
backbone that has been described previously (Lohrengel et al., 2005;
Neumann et al., 2005). This system is amenable to accepting diverse env
genes, and facilitates substitution of virtually the entire coding region
(only 36 and 6 amino acids at the N and C terminus respectively are
derived from NL4.3). We have previously shown that patient-derived
Envs retain their entryphenotype in comparisonwith theprimary isolate,
indicating that the NL4.3 backbone is neutral to Env entry properties
(Neumannet al., 2005). Peripheral bloodmononuclear cells (PBMC)were
isolated from the whole blood of a normal, seronegative donor by ﬁcoll-
hypaque centrifugation. CD8-depleted PBMC cultures were prepared by
negative selection using Dynabeads (Invitrogen). The CD4-enriched
PBMC were cultured in complete RPMI for 3 days in the presence of
3 mg/ml phytohemagglutinin (PHA) for activation prior to infection.
Infected culturesweremaintained in complete RPMI supplementedwith
30 U/ml recombinant human IL-2 (Roche) for up to 10 days. Every two
days, 200 μl of supernatantwas collected for p24 analysis (Perkin-Elmer),
and this volumewas replacedwith fresh completemediawith IL-2.MDM
were prepared fromwhole blood as described in (Salazar-Gonzalez et al.,
2009). Brieﬂy, 3×106 PBMCperwellwere subject to adherence for 2 h in
a 24-well plate, andnon-adherent cellswere aspirated off. The remaining
cells were incubated in DMEM with 10% Giant Tumor Cell-Conditioned
Media (GCT) (Irvine Scientiﬁc), 10% Human AB Serum (Sigma) and
50 ng/ml recombinant human Macrophage Colony-Stimulating Factor
(rhMCSF) (R&D Systems). After 3 days, the cells were washed 3 times
with PBS and media was replaced with 800 μl of Macrophage media
(DMEM+10% FBS (Hyclone)+10% GCT+50 ng/ml rhMCSF). On day 6,
100,000 IU of virus was added in 300 μl serum-free DMEM for 2 h, and
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3 days for 13 days after infection, 250 μl of supernatant was collected for
p24 analysis, and 1.5 ml of media was removed and then replaced with
fresh media. Subtype B Envs NL4.3 and YU-2 and subtype C Env MJ-4
were cloned into the NL4.3 backbone and used as controls for these
experiments. The infectious subtype C proviral cloneMJ4 (contributed by
Drs. Thumbi Ndung'u, Boris Renjifo, and Max Essex) (Ndung'u et al.,
2001) was obtained from the NIH AIDS Research and Reference and
Reagent Program, Division of AIDS, NIAID, NIH.
Receptor-dependent pseudovirus entry assay
Pseudovirus entry assayswere performed as described above except
that a panel of HeLa cells (provided by Drs. Emily Platt and David Kabat,
Oregon Health and Science University) stably transduced to express
varying levels CD4 and CCR5 were used instead of JC53-BL cells and the
Env-deﬁcient subtype B proviral plasmid pNL4.3ΔEnv, kindly provided
by Dr. Ron Collman, expressing a luciferase reporter gene was used
instead of pSG3DEnv (which does not express a reporter gene) (Kabat
et al., 1994; Platt et al., 1998). Brieﬂy, transfection supernatants were
normalized to p24 and equivalent amountswere added perwell in each
experiment to infect each cell line. The cell lines used were JC.53
(1.5×105 CD4 and 1.3×105 CCR5 molecules/cell), JC.10 (1.5×105 CD4
and 2.0×103 CCR5 molecules/cell) and RC.49 (1.0×104 CD4 and
8.5×104 CCR5 molecules/cell).
Statistical analysis
To compare groups, a non-parametric Wilcoxon signed rank test
was used for paired comparisons. All analyses were performed using a
two-tailed p-value in Graphpad Prism 4.0c, and p-values≤0.05 were
considered statistically signiﬁcant.
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